Cargando…

Cancer-associated thrombosis: prevention and treatment

Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Brose, K.M.J., Lee, A.Y.Y.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216419/
https://www.ncbi.nlm.nih.gov/pubmed/18231650
_version_ 1782149144351080448
author Brose, K.M.J.
Lee, A.Y.Y.
author_facet Brose, K.M.J.
Lee, A.Y.Y.
author_sort Brose, K.M.J.
collection PubMed
description Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in some clinical situations. Currently, low molecular weight heparin and warfarin are the most frequently used pharmacologic agents; however, they have their limitations. Other therapeutic options, such as inferior caval filters, are poorly studied and remain controversial. A summary of the most recent evidence on the prevention and treatment of venous thromboembolism in cancer patients is presented here.
format Text
id pubmed-2216419
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-22164192008-01-29 Cancer-associated thrombosis: prevention and treatment Brose, K.M.J. Lee, A.Y.Y. Curr Oncol Medical Oncology Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in some clinical situations. Currently, low molecular weight heparin and warfarin are the most frequently used pharmacologic agents; however, they have their limitations. Other therapeutic options, such as inferior caval filters, are poorly studied and remain controversial. A summary of the most recent evidence on the prevention and treatment of venous thromboembolism in cancer patients is presented here. Multimed Inc. 2008-01 /pmc/articles/PMC2216419/ /pubmed/18231650 Text en 2008 Multimed Inc. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Medical Oncology
Brose, K.M.J.
Lee, A.Y.Y.
Cancer-associated thrombosis: prevention and treatment
title Cancer-associated thrombosis: prevention and treatment
title_full Cancer-associated thrombosis: prevention and treatment
title_fullStr Cancer-associated thrombosis: prevention and treatment
title_full_unstemmed Cancer-associated thrombosis: prevention and treatment
title_short Cancer-associated thrombosis: prevention and treatment
title_sort cancer-associated thrombosis: prevention and treatment
topic Medical Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216419/
https://www.ncbi.nlm.nih.gov/pubmed/18231650
work_keys_str_mv AT brosekmj cancerassociatedthrombosispreventionandtreatment
AT leeayy cancerassociatedthrombosispreventionandtreatment